Indeed, the FASN inhibitor TVB-2640 is under clinical trials to test its efficacy, alone or in combination with paclitaxel, in inhibiting tumor growth and metastasis of different cancers [204], while the inhibition of peroxisome proliferator-activated receptor family members, regulators of FAs synthesis and oxidation and involved in both lipid metabolism and EMT inhibition, induces metastasis in melanoma and increases stemness in prostate cancer [205,206]. The gene discussed is FASN; the disease is prostate cancer.